NASDAQ:FOLD - Amicus Therapeutics Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $15.98 +0.22 (+1.40 %) (As of 07/20/2018 08:27 AM ET)Previous Close$15.76Today's Range$15.52 - $16.0152-Week Range$11.44 - $17.62Volume1.09 million shsAverage Volume1.96 million shsMarket Capitalization$2.97 billionP/E Ratio-5.47Dividend YieldN/ABeta1.38 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease. The company has strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey. Receive FOLD News and Ratings via Email Sign-up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical SymbolNASDAQ:FOLD CUSIP03152W10 Webwww.amicusrx.com Phone609-662-2000 Debt Debt-to-Equity Ratio0.32 Current Ratio4.21 Quick Ratio4.15 Price-To-Earnings Trailing P/E Ratio-5.47 Forward P/E Ratio-12.29 P/E GrowthN/A Sales & Book Value Annual Sales$36.93 million Price / Sales81.55 Cash FlowN/A Price / CashN/A Book Value$2.12 per share Price / Book7.54 Profitability EPS (Most Recent Fiscal Year)($2.92) Net Income$-284,000,000.00 Net Margins-563.98% Return on Equity-60.09% Return on Assets-29.90% Miscellaneous Employees325 Outstanding Shares188,470,000Market Cap$2,970.31 Amicus Therapeutics (NASDAQ:FOLD) Frequently Asked Questions What is Amicus Therapeutics' stock symbol? Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD." How were Amicus Therapeutics' earnings last quarter? Amicus Therapeutics, Inc. (NASDAQ:FOLD) announced its earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.08. The biopharmaceutical company earned $16.70 million during the quarter, compared to analyst estimates of $16.78 million. Amicus Therapeutics had a negative return on equity of 60.09% and a negative net margin of 563.98%. View Amicus Therapeutics' Earnings History. When is Amicus Therapeutics' next earnings date? Amicus Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Amicus Therapeutics. What price target have analysts set for FOLD? 7 equities research analysts have issued twelve-month target prices for Amicus Therapeutics' stock. Their forecasts range from $15.00 to $24.00. On average, they anticipate Amicus Therapeutics' share price to reach $19.50 in the next twelve months. This suggests a possible upside of 22.0% from the stock's current price. View Analyst Ratings for Amicus Therapeutics. What is the consensus analysts' recommendation for Amicus Therapeutics? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Are investors shorting Amicus Therapeutics? Amicus Therapeutics saw a decrease in short interest in the month of June. As of June 29th, there was short interest totalling 26,797,082 shares, a decrease of 8.6% from the June 15th total of 29,318,771 shares. Based on an average daily volume of 2,274,682 shares, the days-to-cover ratio is presently 11.8 days. Approximately 14.6% of the shares of the stock are sold short. View Amicus Therapeutics' Current Options Chain. Who are some of Amicus Therapeutics' key competitors? Some companies that are related to Amicus Therapeutics include Jazz Pharmaceuticals (JAZZ), Alnylam Pharmaceuticals (ALNY), Perrigo (PRGO), Genmab A/S (GNMSF), Beigene (BGNE), Sarepta Therapeutics (SRPT), Nektar Therapeutics (NKTR), Valeant Pharmaceuticals (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Catalent (CTLT), Ionis Pharmaceuticals (IONS), FibroGen (FGEN), Loxo Oncology (LOXO) and United Therapeutics (UTHR). Who are Amicus Therapeutics' key executives? Amicus Therapeutics' management team includes the folowing people: Mr. John F. Crowley, Chairman & CEO (Age 51)Mr. Bradley L. Campbell, Pres, COO & Director (Age 42)Mr. William D. Baird III, Chief Financial Officer (Age 46)Ms. Ellen S. Rosenberg, Gen. Counsel & Corp. Sec. (Age 55)Dr. Jay A. Barth, Chief Medical Officer (Age 54) Has Amicus Therapeutics been receiving favorable news coverage? News headlines about FOLD stock have trended somewhat positive on Friday, Accern Sentiment Analysis reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Amicus Therapeutics earned a news impact score of 0.24 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 47.11 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future. Who are Amicus Therapeutics' major shareholders? Amicus Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Berson & Corrado Investment Advisors LLC (0.02%), Verde Servicos Internacionais S.A. (0.02%), Xact Kapitalforvaltning AB (0.02%), Amalgamated Bank (0.02%), Fox Run Management L.L.C. (0.01%) and Fortaleza Asset Management Inc. (0.00%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Daphne Quimi, Donald J Hayden Jr, Hung Do, Jay Barth, John F Crowley, Kurt J Andrews, Life Sciences Maste Perceptive, Margaret G Mcglynn, Michael Raab, Perceptive Advisors Llc and William D Baird III. View Institutional Ownership Trends for Amicus Therapeutics. Which major investors are selling Amicus Therapeutics stock? FOLD stock was sold by a variety of institutional investors in the last quarter, including Verde Servicos Internacionais S.A. and Fortaleza Asset Management Inc.. Company insiders that have sold Amicus Therapeutics company stock in the last year include Bradley L Campbell, Daphne Quimi, Donald J Hayden Jr, Hung Do, Jay Barth, John F Crowley, Kurt J Andrews, Margaret G Mcglynn, Michael Raab and William D Baird III. View Insider Buying and Selling for Amicus Therapeutics. Which major investors are buying Amicus Therapeutics stock? FOLD stock was purchased by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C., Exane Derivatives, Berson & Corrado Investment Advisors LLC, Amalgamated Bank and Xact Kapitalforvaltning AB. Company insiders that have bought Amicus Therapeutics stock in the last two years include John F Crowley, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Insider Buying and Selling for Amicus Therapeutics. How do I buy shares of Amicus Therapeutics? Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Amicus Therapeutics' stock price today? One share of FOLD stock can currently be purchased for approximately $15.98. How big of a company is Amicus Therapeutics? Amicus Therapeutics has a market capitalization of $2.97 billion and generates $36.93 million in revenue each year. The biopharmaceutical company earns $-284,000,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis. Amicus Therapeutics employs 325 workers across the globe. How can I contact Amicus Therapeutics? Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company can be reached via phone at 609-662-2000 or via email at [email protected] MarketBeat Community Rating for Amicus Therapeutics (NASDAQ FOLD)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 339 (Vote Outperform)Underperform Votes: 196 (Vote Underperform)Total Votes: 535MarketBeat's community ratings are surveys of what our community members think about Amicus Therapeutics and other stocks. Vote "Outperform" if you believe FOLD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FOLD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/20/2018 by MarketBeat.com StaffFeatured Article: What are CEFs?